165 results on '"Sym, Sun Jin"'
Search Results
2. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma
3. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
4. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
5. Evaluation of the efficacy and safety of a 3-weekly TS-1 regimen as adjuvant therapy for stage II and III advanced gastric cancer: A pilot study.
6. PP213 Three-year follow-up of the ATTRACTION-4 Korean subgroup analysis: First-line (1L) nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated, advanced, or recurrent gastric/gastro-esophageal junction (G/GEJ) cancer
7. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis
8. A phase IIa study to evaluate the efficacy of OMT-111 in patients with metastatic colorectal cancer resistant to standard therapies
9. A data-driven approach to a chemotherapy recommendation model based on deep learning for patients with colorectal cancer in Korea
10. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)
11. Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
12. Oncologic outcomes of first-line bevacizumab/FOLFIRI in combination with Ginsenoside-modified nanostructured lipid carrier containing curcumin in unresectable metastatic colorectal cancer patients
13. Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
14. 553 DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial
15. Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients
16. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types
17. A urethral clear cell carcinoma case successfully treated with organ preservation surgery and adjuvant chemoradiation
18. Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia
19. Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
20. The Predictive Value of Tumor Size, Volume, and Markers During Radiation Therapy in Patients With Cervical Cancer
21. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients
22. Machine learning techniques for prediction of recurrence after curative resection in the patients with rectal cancer
23. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
24. Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer
25. Short-course radiotherapy and chemotherapy for conversion surgery in patients with unresectable metastatic rectal cancer: a preliminary case series study
26. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
27. Oxaliplatin (3 months 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.
28. An updated algorithm for the treatment of spinal metastasis
29. Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain
30. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
31. Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).
32. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in patients with gemcitabine-failed metastatic pancreatic cancer: A randomized phase III trial (MPACA-3).
33. sj-pptx-2-tam-10.1177_17588359211042812 – Supplemental material for Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
34. sj-docx-1-tam-10.1177_17588359211042812 – Supplemental material for Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
35. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy
36. Additional file 1 of A data-driven approach to a chemotherapy recommendation model based on deep learning for patients with colorectal cancer in Korea
37. Erratum to: Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types
38. Resistance and aerobic exercise intervention during chemotherapy in patients with metastatic cancer: a pilot study in South Korea
39. Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
40. A data-driven approach to a chemotherapy recommendation model based on deep learning for patients with colorectal cancer in Korea
41. An Ensemble Algorithm Model for the Diagnosis of Colorectal Cancer Based on Machine Learning
42. Mesenchymal stem cell therapy assisted by nanotechnology: a possible combinational treatment for brain tumor and central nerve regeneration
43. Early experience with Watson for oncology in Korean patients with colorectal cancer
44. Intraoperative Frozen Cytology of Central Nervous System Neoplasms: An Ancillary Tool for Frozen Diagnosis
45. Concordance Rate between Clinicians and Watson for Oncology among Patients with Advanced Gastric Cancer: Early, Real-World Experience in Korea
46. Cancer Treatment: Mutual Destruction of Deep Lung Tumor Tissues by Nanodrug-Conjugated Stealth Mesenchymal Stem Cells (Adv. Sci. 5/2018)
47. Mutual Destruction of Deep Lung Tumor Tissues by Nanodrug-Conjugated Stealth Mesenchymal Stem Cells
48. Acute Aortic Thrombosis Following Capecitabine Chemotherapy in a Patient with Colon Cancer
49. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
50. Use of a cognitive computing system for treatment of colon and gastric cancer in South Korea.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.